Jean-Pierre Vuilleumier
Nessuna posizione attualmente
Storia della carriera di Jean-Pierre Vuilleumier
Precedenti posizioni note di Jean-Pierre Vuilleumier
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CTI Invest | Presidente | - | - |
CTI Start-up
 CTI Start-up Miscellaneous Commercial ServicesCommercial Services CTI Start-up provides business consulting and business management services. | Corporate Officer/Principal | - | - |
Malcisbo AG
 Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Direttore Finanziario/CFO | - | - |
Statistiche
Distribuzione geografica
| Svizzera | 4 |
Posizioni
| Director of Finance/CFO | 1 |
| President | 1 |
| Corporate Officer/Principal | 1 |
Settori
| Commercial Services | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 3 |
|---|---|
| CTI Invest | |
CTI Start-up
CTI Start-up Miscellaneous Commercial ServicesCommercial Services CTI Start-up provides business consulting and business management services. | Commercial Services |
Malcisbo AG
Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Health Technology |
